| Literature DB >> 33097666 |
Jessie Huang1, Hong Lam2, Cynthia Koziol-White3,4, Nathachit Limjunyawong5, Donghwa Kim6, Nicholas Kim3, Nikhil Karmacharya4, Premraj Rajkumar7, Danielle Firer2, Nicholas M Dalesio8, Joseph Jude4, Richard C Kurten9, Jennifer L Pluznick7, Deepak A Deshpande10, Raymond B Penn10, Stephen B Liggett6,11, Reynold A Panettieri4, Xinzhong Dong5,12, Steven S An13,4.
Abstract
The recent discovery of sensory (tastant and odorant) G protein-coupled receptors on the smooth muscle ofEntities:
Keywords: G proteins; airway smooth muscle; asthma; olfactory receptor; single-cell analysis
Mesh:
Substances:
Year: 2020 PMID: 33097666 PMCID: PMC7668088 DOI: 10.1073/pnas.2003111117
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205
Fig. 1.Intracellular calcium flux and single-cell contractility evoked by 20 volatile odorants. (A) Odorant-evoked [Ca2+]i was measured using FLIPR Calcium 5 assay. For each well of human ASM cells (∼30,000 cells/well), baseline Calcium 5 dye fluorescence was measured for the first 15 s, and after odorant addition (t = 15 s), the fluorescent reading was continuously measured using a FlexStation 3. For vehicle control, [Ca2+]i was measured in response to 0.1% DMSO. As positive control, cells were stimulated with 10 μM histamine. Data are presented as mean ± SE (n = 3 independent measurements). (B) Dynamic changes in the stiffness of human ASM cells were measured in response to each odorant molecule using OMTC. For each individual human ASM cell, baseline stiffness was measured for the first 60 s, and after odorant addition (t = 60 s), stiffness was continuously measured for the next 240 s. For each cell, stiffness was normalized to its baseline stiffness prior to odorant stimulation (normalized baseline is indicated by dotted line). For vehicle control, stiffness was measured in response to 0.1% DMSO. As positive controls, cell were contracted with 10 μM histamine and relaxed with 10 μM isoproterenol. Data are presented as mean ± SE (n = 92 to 403 individual cell measurements). The colors indicated the odor types of 20 volatile chemicals (putrid, nutty, fruity, floral, caramellic, herbaceous, and minty); the concentrations used for each odorant molecule are shown in .
Fig. 2.Nerol evokes calcium flux, ASM relaxation, and bronchodilation. (A) Nerol-evoked [Ca2+]i and EC50 of [Ca2+]i response in isolated human ASM cells. Data are presented as mean ± SE (n = 90 to 123 cells per group). (B) Nerol-induced stiffness changes and EC50 of stiffness response. Data are presented as mean ± SE (n = 124 to 219 individual cell measurements). (C) Representative images of small airways before and after constricted with 10 μM carbachol (for 10 min), followed by stimulation with increasing doses of nerol (5 min for each dose). After nerol exposures, lung slices were relaxed with forskolin (1 μM) as positive control. (D) Individual hPCLS responses to increasing doses of nerol. Nerol-induced bronchodilation was measured in a total of 12 hPCLSs derived from three different nonasthmatic lung donors. To control for random effects from multiple lung slices from the same donor, we applied a linear mixed effect model using SAS V.9.2 (SAS Institute). ns, not significant.
Fig. 3.The role for classical pain-, temperature-, and itch-sensitive TRP channels on nerol-induced ASM responses. Human ASM cells were treated for 10 min with 5 μM BCTC, 30 μM HC-030031, or 5 μM capsazepine, and then stimulated with 1 mM nerol. For vehicle control, cells were treated for 10 min with 0.1% DMSO. Nerol-induced [Ca2+]i (A) and stiffness changes (B) were measured using Fura-2 and OMTC, respectively. Data are presented as mean ± SE (A, n = 94 to 153 individual cell measurements; B, n = 140 to 281 individual cell measurements). Arrows indicated the time at which nerol was added.
Fig. 4.Human ASM cells express OR2W3. (A) Expression of OR2W3 transcripts in human ASM cells was detected using PCR with (+) or without (−) reverse transcriptase. Full-length OR2W3 is indicated at 945 bp. (B) PCR was also applied to RNAs isolated from cells derived from three additional nonasthmatic lung donors (N1 to N3); PCR products were subsequently run on an agarose gel with or without reverse transcriptase. (C) Protein expression of OR2W3 (35 kDa) was assessed by Western blot in human ASM cells derived from three nonasthmatic lung donors (N1 to N3). Tubulin (50 kDa) was used as loading control. (D) Transcript levels of OR2W3 and (E) nerol-induced ASM relaxation in cells derived from six nonasthmatic and six asthmatic lung donors. Group mean of nerol-induced ASM relaxation is presented as percent change from the respective baseline stiffness.
Fig. 5.OR2W3-evoked calcium flux causes ASM relaxation. (A) Short hairpin RNAs complementary to OR2W3 mRNAs markedly knockdown OR2W3, but not other ORs and β2-adrenergic receptor (ADRB2) in human ASM cells. Data are presented as mean ± SE (n = 3 independent measurements). We used Kruskal–Wallis test and applied Dunn’s method for multiple comparisons. P values indicate the statistical differences from shControl. (B) Peak [Ca2+]i and (C) stiffness changes to nerol in shOR2W3 vs. shControl cells. Data are presented as mean ± SE (control shRNA, n = 282 to 377; OR2W3 shRNA #1, n = 266 to 368; OR2W3 shRNA #2, n = 210 to 345 individual cell measurements). (B and C) We used ANOVA with adjusting for multiple comparisons by applying the Dunnet’s method. P values indicate the statistical differences from shControl. *P < 0.05, **P < 0.01.
Fig. 6.OR2W3-evoked ASM relaxation is divergent from TAS2R signaling and accompanies membrane depolarization. (A) Human ASM cells were treated for 10 min with gallein (20 μM), U73122 (1 μM), iberiotoxin (10 nM), or charybdotoxin (10 nM), and then stimulated with 1 mM nerol. For vehicle control, cells were treated for 10 min with 0.1% DMSO. For each treatment group, baseline stiffness was measured for the first 60 s, and after nerol addition (t = 60 s, arrow), stiffness was continuously measured for the next 240 s. To satisfy the normal distribution assumptions associated with ANOVA, cell stiffness data (steady-state baseline and nerol-induced stiffness) were converted to log scale prior to analyses. Data are presented as mean ± SE (n = 140 to 306 individual cell measurements). (B) To chelate extracellular calcium, human ASM cells were treated for 10 min with 2 mM EGTA. To deplete calcium from the intracellular stores, human ASM cells were treated for 20 min with 10 μM thapsigargin (19, 43). ASM cells were then stimulated with 1 mM nerol or 10 μM histamine. Data are presented as mean ± SE (n = 157 to 270 individual cell measurements). We used ANOVA with adjusting for multiple comparisons by applying the Dunnet’s method. Treatment groups (EGTA and thapsigargin) were compared with respective Controls for nerol or histamine stimulation. (C) Dynamic changes in membrane potential with increasing doses of nerol added at 30 s (arrow) and followed up to 250 s. (D) Membrane potential (area under curve, AUC) evoked by nerol in comparison to 10 μM histamine (His) and 1 mM chloroquine (CQ). Data are presented as mean ± SE (n = 3 independent measurements). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (unpaired t test). ns, not significant.
Fig. 7.OR2W3-evoked chemosensory responses are tuned to Ca2+-activated Cl− channels. (A) Nerol-induced changes in membrane potential were measured in cells treated with Ca2+-activated Cl− (CaC) channel inhibitor (100 μM CaCCinh-A01). For vehicle control, cells were treated with 0.1% DMSO. Arrow indicates time (t = 20 s) at which nerol was added. Data are presented as mean ± SE (n = 3 independent measurements). ****P < 0.0001 (area under the curve [AUC], unpaired t test). (B) Human ASM cells were treated for 10 min with or without CaCCinh-A01 (10 and 100 μM) and then contracted with 10 μM histamine (histamine was added at t = 60 s, arrow). Data are presented as mean ± SE (n = 228 to 326 cells). ANOVA was applied after data transformation. *P < 0.05. (C) Histamine-contracted cells were subsequently stimulated with 1 mM nerol. For each individual cell, stiffness was normalized to its stiffness prior to nerol stimulation (nerol was added at t = 60 s, arrow). Data are presented as mean ± SE (n = 182 to 319 individual cell measurements). RFU, relative fluorescence units.
Fig. 8.OR2W3-induced ASM relaxation is inhibited by pharmacological blockers of CFTR. (A–C) Human ASM cells were treated with or without 100 μM CFTRinh-172 for 10 min. Using OMTC, we measured the stiffness changes in response to A 10 μM isoproterenol, (B) 250 μM chloroquine, and (C) 1 mM nerol. For each individual cell, stiffness changes were normalized to its respective baseline stiffness. Data are presented as mean ± SE (A, n = 97 to 168; B, n = 144 to 145; C, n = 52 to 185 individual cell measurements).
Fig. 9.Conceptual model of OR2W3-evoked ASM relaxation and bronchodilation. Activation of the odorant receptor OR2W3, a GPCR expressed on human ASM cells causes Ca2+ release through PLCβ-IP3 signaling leading to decline in Ca2+ in the intracellular store [endo(sarco)plasmic reticulum, ER/SR]. The reduction in ER Ca2+ initiates extracellular calcium influx through the SOCE pathway via activation of Stim1 and its subsequent physical interactions with Orai1 at the discrete cellular microdomains. Ca2+ flux through store-operated calcium channels leads to plasma membrane depolarization and is potentiated by a cooperative activation of TMEM16A and CFTR localized at the same junction between plasma membrane and the ER/SR. The action of the latter causes Cl− uptake into the SR, facilitating Ca2+ sequestration that results in a decrease in cytosolic calcium concentration promoting ASM relaxation.